VEGFA and neoplasm: Innovations in liquid biopsy methodologies, as highlighted by the CIRCULATE-PRO study, now incorporate circulating tumor DNA (ctDNA)-based ANGPT2/VEGFA biomarkers (AUC=0.82) into National Comprehensive Cancer Network (NCCN) guidelines, thereby facilitating personalized aflibercept therapy (20, 21).